Drug Profile


Alternative Names: KAE-609; KAW-609; NITD-609

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Medicines for Malaria Venture; Novartis
  • Class Antimalarials; Carbolines; Indoles; Pyridones; Small molecules; Spiro compounds
  • Mechanism of Action Cation transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 13 Nov 2017 Phase-II clinical trials in Malaria in Mali (PO) (NCT03334747)
  • 01 Jul 2015 Phase-I clinical trials in Malaria in Australia (PO) (NCT02543086)
  • 24 Jun 2015 Phase II development is ongoing in Vietnam and Thailand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top